Reglagene is discovering new medications that attack cancer’s weaknesses
Reglagene leverages Quadruplex Master Switch Technology (QMST) to create new medicines that help cancer patients. Reglagene aspires to be the world’s leader in the creation of therapies that work through quadruplexes, DNA structures that selectively control the behavior of individual genes.
Pharmaceutical companies now in-license most of their product portfolios from innovator companies such as Reglagene, especially in the oncology sector. We will earn revenue by licensing the intellectual property (patents) around the new medicines we create to pharmaceutical partners, a $30B market. We are the only company that harnesses Quadruplex Master Switch Technology to discover new medicines.
Reglagene is based on technology coming from the University of Arizona and boasts an accomplished team of scientists and industry-leading experts, as well as world-renowned scientific and pharmaceutical advisors.
Unlike gene editing technologies, Reglagene’s approach results in therapeutic effects that last only as long as the medicine is on board. This means that once the treatment is ended and the cancer has been eliminated, the body will return to its natural, healthy state.
VARIABLE CONTROL OF GENE EXPRESSION
Reglagene’s technology is not a binary turning of genes on or off. Depending on the amount of medicine on board and the desired effect, gene activity can be dialed up or down depending on the therapeutic need.
Quadruplex Master Switch Technology takes advantage of the unique structural features of each quadruplex to identify medicines that act on specific genes to create targeted therapies based on the genetic makeup of a patient’s tumor.
A THERAPEUTIC APPROACH
We leverage the advantages of small molecules: variable routes of administration, including oral and iv.; lowest cost of goods; and well-traveled development and regulatory mechanisms.
GENE REGULATION TECHNOLOGY
NEWS & UPDATES
1703 E Mabel St | Tucson, AZ 85721 | USA